Lung Assessment Device Market Size, Share, and Growth Forecast, 2026 - 2033

The global lung assessment device market size is likely to be valued at US$ 16.2 billion in 2026 and is estimated to reach US$ 26.1 billion by 2033, growing at a CAGR of 7.0% during the forecast period 2026 - 2033.

Growth is expected to reflect rising respiratory disease burdens, population aging, and increasing demand for earlier detection of pulmonary dysfunction. Regulatory emphasis on medical device safety, diagnostic accuracy, and clinical performance is likely to influence product development and purchasing decisions.

Wider adoption of connected diagnostic technologies, portable monitoring equipment, and digital pulmonary assessment platforms is expected to expand access to respiratory testing. Investment in hospitals, specialty clinics, ambulatory facilities, and home-based care is likely to support broader deployment.

Driver - Digitalization of respiratory diagnostics and connected monitoring

Technology adoption is changing how respiratory function is measured, interpreted, and monitored. Portable spirometers, digital pulse oximeters, connected respiratory monitors, and software-enabled pulmonary function systems can improve the accessibility of test results and support more consistent clinical workflows. Digital connectivity allows selected measurements to be transferred into electronic health records or remote monitoring platforms, reducing manual data entry and improving continuity between clinical visits. Automated interpretation can help clinicians identify patterns that warrant further investigation, although diagnostic decisions still require appropriate clinical assessment.

Regulatory scrutiny is also influencing device development. In January 2025, the US Food and Drug Administration (FDA) issued draft guidance addressing clinical and nonclinical performance testing, labeling, and premarket submissions for medical pulse oximeters. This initiative highlights the importance of measurement reliability and transparent device labeling. Manufacturers that combine validated sensing technology with practical software integration can improve clinical acceptance.

Restraint - High equipment acquisition and maintenance costs

Advanced pulmonary function systems and body plethysmographs require dedicated equipment, suitable installation environments, calibration, and trained personnel. These requirements can increase the total cost of ownership for smaller hospitals, specialty clinics, and healthcare providers operating under constrained capital budgets. Maintenance contracts, replacement sensors, consumables, and periodic quality checks create recurring expenses after installation.

When testing volumes remain low, fixed costs are spread across fewer procedures, weakening equipment economics. Providers may delay upgrades or select less expensive devices, limiting demand for advanced systems. Manufacturers can face longer sales cycles and pricing pressure when purchasers prioritize initial acquisition cost over lifetime performance.

Opportunity - Expansion of home-based respiratory monitoring

Home-based care creates an opportunity for manufacturers to develop compact, easy-to-use devices that support prescribed respiratory monitoring outside conventional clinical environments. Portable spirometers, pulse oximeters, and peak flow meters can help eligible patients collect measurements between appointments, while connected platforms can transmit selected results to healthcare professionals. A practical growth pathway involves designing devices around clear patient instructions, accessible interfaces, reliable measurement quality, and integration with established remote care workflows.

Manufacturers can work with healthcare providers to validate monitoring protocols and determine which readings require clinical review. The commercial opportunity lies in extending appropriate respiratory assessment beyond hospitals without replacing necessary in-person diagnosis.

Expansion will depend on reimbursement arrangements, clinical acceptance, patient adherence, and connectivity availability. Companies can prioritize partnerships with hospital networks, home healthcare providers, and digital health platforms to build repeatable distribution channels. Regulatory requirements for intended use, labeling, cybersecurity, and clinical performance should guide product design from the outset. Manufacturers can also offer training, device servicing, and data management as part of broader solutions.

Product Type Insights

Spirometers are expected to lead the market, accounting for 42% of the revenue share in 2026. Their role in measuring airflow and lung function supports routine respiratory assessment and monitoring. For example, primary care providers use spirometry to evaluate suspected airflow obstruction and monitor selected patients with chronic respiratory conditions. Standardized testing protocols and portable device formats can expand adoption across clinical settings.

Pulmonary function systems represent the fastest-growing segment, propelled by demand for comprehensive respiratory evaluation and improved diagnostic workflows. These systems can combine multiple measurements to support assessment of complex pulmonary conditions. For example, specialty clinics may use integrated testing equipment to evaluate patients requiring more detailed functional assessment. Digital reporting and automated workflow support can improve operational efficiency. The growth ranking remains provisional until comparable segment-level forecasts are available.

End-User Insights

Hospitals are projected to lead the market, capturing around 57% share in 2026. Their broad clinical capabilities support the use of spirometers, pulse oximeters, capnography, and advanced pulmonary function systems. For example, hospital respiratory departments use oxygen saturation monitoring during patient assessment and selected procedures. High patient throughput and multidisciplinary care requirements can support equipment purchasing.

Home care is anticipated to be the fastest-growing segment, fueled by demand for convenient respiratory monitoring and continued development of portable diagnostic technologies. Remote monitoring can help eligible patients record measurements between scheduled appointments. For example, a patient may use a prescribed pulse oximeter to track oxygen saturation under a clinician-directed care plan. Simple interfaces, reliable measurements, and secure data transmission can support wider adoption. Growth will depend on reimbursement, patient adherence, clinical suitability, and access to connected care services.

North America Lung Assessment Device Market Trends

North America is anticipated to be the leading region, accounting for around 40% market share in 2026. Established healthcare infrastructure supports demand for spirometers, pulse oximeters, capnography, and advanced pulmonary testing systems. The U.S. benefits from established diagnostic networks and medical device distribution. Canada contributes through hospital-based respiratory care and outpatient testing. FDA oversight of pulse oximeter performance encourages manufacturers to strengthen validation and labeling.

U.S. Lung Assessment Device Market Insights

The U.S. is anticipated to dominate the North America market, capturing nearly 89% of the regional market share in 2026. Demand is expected to stem from established respiratory diagnostic services and investment in connected monitoring technologies. Hospitals, pulmonary clinics, and home healthcare providers support demand for different device categories. FDA performance requirements influence product development and regulatory submissions. Manufacturers can strengthen adoption through validated measurements, interoperability, and clinician training. Purchasing decisions are likely to reflect clinical suitability, maintenance costs, and reimbursement conditions.

Canada Lung Assessment Device Market Insights

Canada accounts for 11% of the North American market share in 2026, supported by public healthcare delivery, hospital procurement, and respiratory assessment services. Hospitals and specialty clinics require spirometers, pulse oximeters, and pulmonary function systems for diagnosis and follow-up. Remote monitoring may improve access for patients living far from specialist facilities. Procurement decisions are likely to emphasize equipment reliability, operating costs, and servicing availability. Suppliers can expand through regional distributors and partnerships with healthcare institutions.

Europe Lung Assessment Device Market Trends

Europe is projected to command nearly 30% share of the market in 2026, supported by established healthcare infrastructure and regulatory oversight. The European Union Medical Device Regulation shapes product conformity, clinical evidence, and post-market surveillance. Hospitals and specialist clinics require reliable equipment for respiratory diagnosis and monitoring. Germany, the United Kingdom, and France provide important healthcare markets. Manufacturers can compete through measurement accuracy, digital reporting, and technical support.

Germany Lung Assessment Device Market Insights

Germany is projected to account for 29% of the European market share in 2026. The country is sustaining demand through hospital infrastructure, specialist pulmonary services, and established medical technology procurement. Pulmonary clinics require reliable functional testing systems, while hospitals use pulse oximeters and capnography for patient monitoring. Regulatory compliance and equipment servicing influence supplier selection.

U.K. Lung Assessment Device Market Insights

The U.K. is anticipated to hold about 28% share of the European market in 2026. The U.K. is expected to maintain demand through NHS diagnostic services, specialist respiratory care, and community healthcare programs. Hospitals and community diagnostic services can support demand for portable and laboratory-based testing equipment. Procurement decisions are likely to emphasize clinical evidence, device reliability, and lifecycle costs. Suppliers can pursue institutional contracts and support training to improve appropriate equipment use.

Asia Pacific Lung Assessment Device Market Trends

Asia Pacific is likely to be the fastest-growing regional market, driven by expanding healthcare infrastructure, growing demand for respiratory diagnostics, and broader access to portable equipment. China, Japan, and India present different adoption conditions because healthcare capacity, procurement budgets, and specialist availability vary. Regional manufacturers can compete through affordability and distribution reach. Demand for connected monitoring is also likely to expand.

China Lung Assessment Device Market Insights

China is expected to dominate the Asia Pacific market, commanding around 28% share in 2026. China is likely to benefit from domestic medical device production, hospital investment, and expanding respiratory diagnostic capacity. This percentage applies to spirometers rather than the complete lung assessment device market. Hospitals and outpatient facilities can support demand for pulmonary function systems and portable monitors. Domestic suppliers may compete through cost efficiency and local servicing. Product registration, measurement reliability, and clinical suitability will influence purchasing decisions.

India Lung Assessment Device Market Insights

India is estimated to hold nearly 20% share of the Asia Pacific market in 2026. India offers immense growth opportunities through expanding diagnostic services, respiratory disease management, and demand for affordable monitoring equipment. This is not the country share of the complete lung assessment device market. Hospitals, specialty clinics, and selected home healthcare programs can support equipment adoption. Manufacturers can improve access through local distribution, clinician education, and cost-effective device designs. Procurement budgets and service availability will influence deployment.

The global lung assessment device market is characterized by competition across established medical technology companies, specialized respiratory diagnostic manufacturers, and suppliers of portable monitoring devices. Competition reflects differences in measurement capabilities, clinical validation, regulatory compliance, product reliability, and integration with healthcare systems. Abbott, Philips, Medtronic, Masimo, and Baxter participate in relevant medical device or monitoring categories. Their broader portfolios do not establish their individual revenue shares in this specific market.

Competitive positioning depends on product specialization, distribution reach, manufacturing capabilities, and after-sales support. Advanced pulmonary function equipment competes on testing capabilities, while portable devices compete on usability and accessibility. Suppliers that combine reliable measurements, practical integration, and cost-effective servicing can improve their prospects in institutional and home healthcare channels.

Key Industry Developments

• In October 2026, Biodesix partnered with Vanderbilt University and Vanderbilt Health to develop an AI-powered radiomics test for lung nodule risk assessment. The initiative combined blood-based biomarkers, CT imaging data, and artificial intelligence to improve lung cancer risk assessment. The test was designed to complement the existing Nodify Lung portfolio, with commercial availability expected in 2028.
• In August 2026, SimonMed partnered with Optellum to integrate artificial intelligence (AI)-powered lung nodule risk assessment into its existing medical imaging workflow. The integration incorporated Optellum Lung Cancer Prediction (LCP) AI into routine chest CT examinations to assess the malignancy risk of eligible incidentally detected lung nodules. The technology generated validated risk scores to support clinical decision-making and complemented SimonMed existing AI capabilities for nodule measurement and growth tracking.